# Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression

> **NCT07655622** · PHASE1,PHASE2 · RECRUITING · sponsor: **Second Affiliated Hospital of Nanchang University** · enrollment: 45 (estimated)

## Conditions studied

- Non-Small-Cell Lung Cancer

## Interventions

- **DRUG:** Vebreltinib
- **DRUG:** Furmonertinib 80mg

## Key facts

- **NCT ID:** NCT07655622
- **Lead sponsor:** Second Affiliated Hospital of Nanchang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-03
- **Primary completion:** 2027-12-03
- **Final completion:** 2029-06-03
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-06-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07655622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07655622, "Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07655622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*